GenCore version 5.1.3

OM protein - protein search, using sw model

Run on: January 16, 2003, 16:34:37 ; Search time 57.0857 Seconds
(without alignments)
28.011 Million cell updates/sec

Title: US-09-856-070-21
Perfect score: 60
Sequence: 1 EELMLRLQDYEE 12

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	60	100.0	12	22	AAB82038	Human hepreceptor
2	60	100.0	13	22	AAB82037	Human hepreceptor
3	60	100.0	34	22	AAB82020	Human hepreceptor
4	60	100.0	436	22	AAG73954	Human colon cancer
5	60	100.0	586	20	AAY27443	Amino acid sequenc
6	60	100.0	622	22	AAU30004	Novel human secret
7	60	100.0	635	21	AAR53356	Human colon cancer
8	55	91.7	11	22	AAB82039	Human hepreceptor
9	52	86.7	52	22	AAU33060	Novel human secret
10	41	68.3	27	20	AAY27444	Antennapedia inter
11	41	68.3	344	22	ABG29165	Novel human diagno
12	39	65.0	57	22	ABB39680	Peptide #7186 enco
13	39	65.0	57	22	AAM60396	Human brain expres
14	39	65.0	57	22	AAM73032	Human bone marrow
15	39	65.0	57	22	AAM33256	Peptide #7293 enco
16	39	65.0	57	23	ABG42876	Human peptide enco
17	39	65.0	405	11	AAR08119	CDX, a MILA involv
18	39	65.0	405	12	AAR13752	GDP Fuc:Beta D Gal
19	39	65.0	405	13	AAR28840	Hela cell fucosylt
20	39	65.0	405	15	AAR45937	A glycosyltransfer
21	39	65.0	405	18	AAW13641	Human alpha(1,3)-f
22	39	65.0	405	18	AAW11821	Human myeloid deri
23	39	65.0	429	22	ABG19048	Novel human diagno
24	39	65.0	429	22	AAG74841	Human colon cancer
25	39	65.0	496	15	AAR45938	A glycosyltransfer
26	39	65.0	802	22	ABG19045	Novel human diagno
27	39	65.0	880	22	AAB96332	Putative P. abyssi
28	39	65.0	2645	22	ABG20077	Novel human diagno
29	38	63.3	1387	21	AAY95441	Caenorhabditis ele
30	37	61.7	21	23	AAU89857	Insulin/insulin-li
31	37	61.7	286	22	AAB96752	Putative P. abyssi
32	37	61.7	299	22	AAU14636	Novel bone marrow
33	37	61.7	306	19	AAM52940	Pseudomonas sp. P2
34	37	61.7	353	22	AAU14730	Novel bone marrow
35	37	61.7	443	22	ABB68491	Drosophila melanog
36	37	61.7	847	22	ABG17337	Novel human diagno
37	37	61.7	1200	21	AAB19313	Amino acid sequenc
38	36	60.0	284	21	AAG30197	Arabidopsis thalia
39	36	60.0	284	21	AAG49452	Arabidopsis thalia
40	36	60.0	293	21	AAG30196	Arabidopsis thalia
41	36	60.0	293	21	AAG49451	Arabidopsis thalia
42	36	60.0	405	12	AAR14404	Protein 7.2 (1.3-f
43	36	60.0	484	21	AAG31854	Arabidopsis thalia
44	36	60.0	530	12	AAR14405	Protein 1 (1.3 fuc
45	36	60.0	602	22	AAB93874	Human protein sequ

ALIGNMENTS

RESULT 1
AAB82038
ID AAB82038 standard; peptide; 12 AA.
XX
AC AAB82038;
XX
DT 13-JUN-2001 (first entry)
XX
DE Human hepreceptor domain A binding peptide Sup#2122.
XX
KW Human; hepreceptor; cytostatic; anti-HIV; antibiotic;
KW Lectinpid; immune response inducer; ataxia; infectious diseases; cancer;
KW HIV related dementia.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Modified-site 10
FT /note= "Optionally phosphorylated"
XX
PN GB2354241-A.
XX
PD 21-MAR-2001.
XX
PF 17-SEP-1999; 99GB-0021881.
XX
PR 17-SEP-1999; 99GB-0021881.
XX
PA (HOLM/) HOLMS R D.
XX
PI Holms RD;
XX
DR WPI; 2001-293287/31.

```
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer -
XX
PS   Claim 24; Page 36; 42pp; English.
XX
CC   The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC   the structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present peptide binds to domain A of the
CC   hepreceptor (AAB82019).
XX
SQ   Sequence   12 AA;

  Query Match             100.0%;  Score 60;  DB 22;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 0.0023;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EELMLRLQDYEE 12
           ||||||||||||
Db       1 EELMLRLQDYEE 12


RESULT 2
AAB82047
ID   AAB82047 standard; peptide; 14 AA.
XX
AC   AAB82047;
XX
DT   14-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain A binding peptide Rupe2032.
XX
KW   Human; hepreceptor; cytostatic; anti-HIV; antibiotic;
KW   nootropic; immune response inducer, ezrin, infectious diseases, cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   11
FT                   /note= "optionally phosphorylated"
XX
PN   GB2354241-A.
XX
PD   21 MAR 2001.
XX
PF   17-SEP 1999;   99GB 0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001-293287/31.
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer -
XX
PS   Claim 22; Page 36; 42pp; English.
XX
CC   The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC   the structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present peptide binds to domain A of the
CC   hepreceptor (AAB82019).
XX
SQ   Sequence   13 AA;

  Query Match             100.0%;  Score 60;  DB 22;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 0.0025;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EELMLRLQDYEE 12
           ||||||||||||
Db       2 EELMLRLQDYEE 13


RESULT 3
AAB82020
ID   AAB82020 standard; peptide; 34 AA.
XX
AC   AAB82020;
XX
DT   14-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain B.
XX
KW   Human; hepreceptor domain B; cytostatic; anti-HIV; antibiotic;
KW   nootropic; immune response inducer; ezrin, infectious diseases, cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   14
FT                   /note= "Optionally phosphorylated"
XX
PN   GB2354241-A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001-293287/31.
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer -
XX
PS   Claim 5; Page 36; 42pp; English.
XX
CC   The present sequence is domain B of human hepreceptor of human ezrin. The
CC   hepreceptor is a novel active site in human ezrin. Ezrin regulates the
CC   structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present sequence assembles into two
CC   anti-parallel helices with hepreceptor domain A (see AAB82019).
XX
SQ   Sequence   34 AA;

  Query Match             100.0%;  Score 60;  DB 22;  Length 34;
  Best Local Similarity   100.0%;  Pred. No. 0.0066;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EELMLRLQDYEE 12
           ||||||||||||
Db       5 EELMLRLQDYEE 16
```

```
RESULT 4
AAG73954
ID   AAG73954 standard; Protein, 436 AA.
XX
AC   AAG73954;
XX
DT   03-SEP-2001  (first entry)
XX
DE   Human colon cancer antigen protein SEQ ID NO:4718.
XX
KW   Human; colon cancer, colon cancer antigen, diagnosis, detection;
KW   colorectal carcinoma.
XX
OS   Homo sapiens.
XX
PN   WO200122920-A2.
XX
PD   05-APR-2001.
XX
PF   28-SEP-2000; 2000WO US26524.
XX
PR   29-SEP-1999;   99US-0157137.
PR   03-NOV-1999;   99US-0163280
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Ruben SM,  Barash SC,  Birse CE,  Rosen CA;
XX
DR   WPI; 2001-235357/24.
DR   N-PSDB; AAH33385.
XX
PT   Nucleic acids encoding 4277 human colon cancer associated polypeptides,
PT   useful for preventing, diagnosing and/or treating colorectal cancers .
XX
PS   Claim 11; Page 652-652; 980pp; English.
XX
CC   AAH32943 to AAH37195 and AAG73514 to AAC77788 represent human colon
CC   cancer associated nucleic acid molecules (N) and proteins (P), where
CC   the proteins are collectively known as colon cancer antigens. The colon
CC   cancer antigens have cytostatic activity and can be used in gene
CC   therapy and vaccine production. N and P may be used in the prevention,
CC   diagnosis and treatment of diseases associated with inappropriate P
CC   expression. For example, N and P may be used to treat disorders
CC   associated with decreased expression by rectifying mutations or deletions
CC   in a patient's genome that affect the activity of P by expressing
CC   inactive proteins or to supplement the patients own production of P.
CC   Additionally, N may be used to produce the colon cancer-associated Ps,
CC   by inserting the nucleic acids into a host cell and culturing the cell
CC   to express the proteins. N and P can be used in the prevention, diagnosis
CC   and treatment of colorectal carcinomas and cancers. AAH37196 to AAH37204
CC   and AAB77789 represent sequences used in the exemplification of the
CC   present invention.
CC   N.B. Pages 666 to 682 and page 7053 of the sequence listing were
CC   missing at time of publication, meaning no sequences are present for
CC   SEQ ID NO:1027 to 1052, 7927 and 7922
XX
SQ   Sequence   436 AA;

  Query Match             100.0%;  Score 60;  DB 22;  Length 436;
  Best Local Similarity   100.0%;  Pred. No. 0.088;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EELMLRLQDYEE 12
           ||||||||||||
Db     195 EELMLRLQDYEE 206


RESULT 5
AAY27443
ID   AAY27443 standard; protein; 586 AA.
XX
AC   AAY27443;
XX
DT   26-NOV-1999  (first entry)
XX
DE   Amino acid sequence of human ezrin polypeptide.
XX
KW   Pharmaceutical; ezrin; mutant; tumor; metastasis; human.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 354
FT                   /note= "the Tyr at this position can be mutated
FT                   (preferably to a Phe) to construct an
FT                   ezrin mutant of the invention"
XX
PN   WO9947150-A2.
XX
PD   23-SEP-1999.
XX
PF   18-MAR-1999;   99WO-EP02054.
XX
PR   18-MAR-1998;   98US-0040725.
XX
PA   (CURI-) INST CURIE.
PA   (CNRS ) CNRS CENT NAT RECH SCI.
XX
PI   Arpin M,  Crepaldi T,  Gautreau A,  Louvard D;
XX
DR   WPI; 1999-561851/47.
XX
PT   New composition for prevention and treatment of tumors and metastasis
PT   -
XX
PS   Example 1; Fig 1; 31pp; English.
XX
CC   The invention provides a pharmaceutical composition containing ezrin
CC   protein, RNA or DNA mutated on tyrosine 353, or a functional fragment
CC   or derivative of the ezrin mutant. The new composition is useful for
CC   prevention and/or treatment of tumors, and especially metastasis. The
CC   present sequence represents the amino acid sequence of human ezrin
CC   (before the maturation by deletion of the first amino acid Met).
XX
SQ   Sequence   586 AA;

  Query Match             100.0%;  Score 60;  DB 20;  Length 586;
  Best Local Similarity   100.0%;  Pred. No. 0.12;
  Matches   12;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 EELMLRLQDYEE 12
           ||||||||||||
Db     345 EELMLRLQDYEE 356


RESULT 6
AAU30004
ID   AAU30004 standard; Protein; 622 AA.
XX
AC   AAU30004;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Novel human secreted protein #495.
XX
KW   Human; vaccination; gene therapy; nutritional supplement;
KW   stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW   immune suppression; immune stimulation; anti-inflammatory; leukaemia.
XX
OS   Homo sapiens.
XX
PN   WO200179449-A2.
XX
PD   25-OCT-2001.
```

XX
PF 16-APR-2001; 2001WO-US08656.
XX
PR 18-APR-2000; 2000US-0552929.
PR 26-JAN-2001; 2001US-0770160.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-611725/70.
XX
PT Nucleic acids encoding a range of human polypeptides, useful in genetic
PT vaccination, testing and therapy -
XX
PS Claim 20; Page 219; 765pp; English.
XX
CC The invention relates to novel human secreted polypeptides. The
CC polypeptides and antibodies to the polypeptides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of polypeptide. The polypeptides are also useful for
CC identifying agents (agonists and antagonists) that bind to them. Cells
CC expressing the proteins are useful for identifying a therapeutic agent
CC for use in treatment of a pathology related to aberrant expression or
CC physiological interactions of the polypeptide. Vectors comprising
CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation; to regulate haematopoiesis; and in
CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
CC immune suppression and/or stimulation; as anti-inflammatory agents; and
CC in treatment of leukaemias. AAU29510-AAU33804 represent the amino acid
CC sequences of novel human secreted proteins of the invention.
XX
SQ Sequence 622 AA;

Query Match 100.0%; Score 60; DB 22; Length 622;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EELMLRLQDYEE 12
||||||||||||
Db 481 EELMLRLQDYEE 492

RESULT 7
AAB53356
ID AAB53356 standard; Protein; 635 AA.
XX
AC AAB53356;
XX
DT 09-MAR-2001 (first entry)
XX
DE Human colon cancer antigen protein sequence SEQ ID NO:896.
XX
KW Human; colon cancer; colon cancer antigen; diagnosis; detection;
KW identification; cytostatic; cardioactive; neuroprotective; vulnerary;
KW immunomodulatory; muscular; gynaecological; gastrointestinal;
KW nephrotropic; antiinfective; antibacterial; gene therapy; wound;
KW neural disorder; immune system disorder; muscular disorder;
KW reproductive disorder; gastrointestinal disorder; renal disorder;
KW infectious disease; cardiovascular disorder.
XX
OS Homo sapiens.
XX
PN WO200055351-A1.
XX
PD 21-SEP-2000.
XX
PF 08-MAR-2000; 2000WO-US05883.
XX
PR 12-MAR-1999; 99US-0124279.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM;
XX
DR WPI; 2000-587534/55.
DR N-PSDB; AAC98113.
XX
PT Colon cancer associated gene sequences, referred to as colon cancer
PT antigens, useful for the treatment, prevention, and diagnosis of colon
PT disorders such as colon cancer -
XX
PS Claim 11; Page 1449-1451; 2104pp; English.
XX
CC AAC97991 to AAC98763 encode the human colon cancer associated proteins,
CC called human colon cancer antigens, given in AAB54234 to AAB54006. The
CC human colon cancer antigens can have cytostatic, cardioactive, muscular;
CC neuroprotective, immunomodulatory, gynaecological, gastrointestinal,
CC vulnerary, nephrotropic, antiinfective and antibacterial activities, and
CC can be used in gene therapy. The colon cancer antigen polynucleotides,
CC proteins and antibodies to the proteins are useful for the prevention,
CC treatment and diagnosis of colon disorders, such as colon cancer. The
CC polynucleotides may be used in diagnostics and research, such as for
CC chromosome identification, and as hybridisation probes. The proteins
CC may also be used to prevent diseases such as neural disorders, immune
CC system disorders, muscular disorders, reproductive disorders,
CC gastrointestinal disorders, wounds, renal disorders, infectious
CC diseases, and cardiovascular disorders. AAC98764 to AAC98772 and
CC AAB54007 represent sequences used in the exemplification of the present
CC invention.
XX
SQ Sequence 635 AA,

Query Match 100.0%; Score 60; DB 21; Length 635;
Best Local Similarity 100.0%; Pred. No. 0.13;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EELMLRLQDYEE 12
||||||||||||
Db 394 EELMLRLQDYEE 405

RESULT 8
AAB82039
ID AAB82039 standard; peptide; 11 AA.
XX
AC AAB82039;
XX
DT 13-JUN-2001 (first entry)
XX
DE Human hepreceptor domain A binding peptide Rupe2232.
XX
KW Human, heprecceptor, cytostatic; anti-HIV; antibiotic;
KW nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW HIV-related dementia.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Modified-site 9
FT /note- "Optionally phosphorylated"
XX
PN GB2354241-A.
XX
PD 21-MAR-2001.
XX
PF 17-SEP-1999; 99GB-0021881.
XX
PR 17-SEP-1999; 99GB-0021881.
XX
PA (HOLM/) HOLMS R D.
XX
PI Holms RD;

XX
DR WPI; 2001-299287/31
XX
PT Novel regulatory or unfolding peptides of ezrin that binds to
PT Hepreceptor, useful for inducing immune response for treating
PT infectious diseases and cancer
XX
PS Claim 26; Page 37; 40pp; English.
XX
CC The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC the structure of the cortical cytoskeleton to control cell surface
CC topography. The present invention relates to peptides (see AAB82021 to
CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC AAB82046). The hepreceptor binding peptides are useful for inducing
CC immune response, and for treating infectious diseases, cancer and
CC HIV-related dementia. The present peptide binds to domain A of the
CC hepreceptor (AAB82019).
XX
SQ Sequence 11 AA;

Query Match 91.7%; Score 55; DB 22; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.014;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 ELMLRLQDYEE 12
||||||||||||
Db 1 ELMLRLQDYEE 11

RESULT 9
AAU33060
ID AAU33060 standard; Protein; 52 AA.
XX
AC AAU33060;
XX
DT 18-DEC-2001 (first entry)
XX
DE Novel human secreted protein #3551.
XX
KW Human; vaccination, gene therapy, nutritional supplement,
KW stem cell proliferation, haematopoiesis, nerve tissue regeneration,
KW immune suppression; immune stimulation; anti-inflammatory; leukaenia.
XX
OS Homo sapiens.
XX
PN WO200179449-A2.
XX
PD 25-OCT-2001.
XX
PF 16-APR-2001; 2001WO-US08656.
XX
PR 18-APR-2000; 2000US-0552929.
PR 26-JAN-2001; 2001US-0770160.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-611725/70.
XX
PT Nucleic acids encoding a range of human polypeptides, useful in genetic
PT vaccination, testing and therapy -
XX
PS Claim 20; Page 702; 795pp; English.
XX
CC The invention relates to novel human secreted polypeptides. The
CC polypeptides and antibodies to the polypeptides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of polypeptide. The polypeptides are also useful for
CC identifying agents (agonists and antagonists) that bind to them. Cells
CC expressing the proteins are useful for identifying a therapeutic agent
CC for use in treatment of a pathology related to aberrant expression or
CC physiological interactions of the polypeptide. Vectors comprising
CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation; to regulate haematopoiesis; and in
CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
CC immune suppression and/or stimulation; as anti-inflammatory agents; and
CC in treatment of leukaemias. AAU29518 AAU33394 represent the amino acid
CC sequences of novel human secreted proteins of the invention.
XX
SQ Sequence 52 AA;

Query Match 91.7%; Score 55; DB 22; Length 52;
Best Local Similarity 91.7%; Pred. No. 0.2;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EELMLRLQDYEE 12
||||| ||||||
Db 13 EELMLWLQDYEE 24

RESULT 10
AAY27444
ID AAY27444 standard; peptide; 27 AA.
XX
AC AAY27444;
XX
DT 26-NOV-1999 (first entry)
XX
DE Antennapedia internalization sequence in tandem with ezrin fragment.
XX
KW Pharmaceutical; ezrin; mutant; tumor; antennapedia internalization;
KW metastasis; human.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 1
FT /note= "biotinylated"
FT Modified-site 22
FT /note= "optionally phosphorylated"
XX
PN WO9947150-A2.
XX
PD 23-SEP-1999.
XX
PF 18-MAR-1999; 99WO-EP02054.
XX
PR 18-MAR-1998; 98US-0040725.
XX
PA (CURI-) INST CURIE.
PA (CNRS) CNRS CENT NAT RECH SCI.
XX
PI Arpin M, Crepaldi T, Gautreau A, Louvard D;
XX
DR WPI; 1999-561851/47.
XX
PT New composition for prevention and treatment of tumors and metastasis
PT -
XX
PS Example 5; Page 14; 31pp; English.
XX
CC The invention provides a pharmaceutical composition containing ezrin
CC protein, RNA or DNA mutated at tyrosine 354, or a functional fragment
CC or derivative of the ezrin mutant. The new composition is useful for
CC prevention and/or treatment of tumors, and especially metastasis. The
CC present sequence represents an antennapedia internalization sequence in
CC tandem with an ezrin fragment (residues 348-358). This is used in
CC experiments of p85 interaction with phosphorylated ezrin peptides.
XX
SQ Sequence 27 AA;

Query Match 68.3%; Score 41; DB 20; Length 27;

Best Local Similarity 100.0%; Pred. No. 6.1;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 LRLQDYEE 12
||||||||
Db 17 LRLQDYEE 24

RESULT 11
ABG29165
ID ABG29165 standard; Protein; 344 AA.
XX
AC ABG29165;
XX
DT 13-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #29156
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US09841.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0644167.
XX
PA (HYSE) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS93352.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 59524; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010 ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 344 AA;

Query Match 68.4%; Score 41; DB 22; Length 344;
Best Local Similarity 72.7%; Pred. No. 79;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 EELMLRLQDYE 11
:|||||:|||
Db 278 KELMLRQKDYE 288

RESULT 12
ABB39680
ID ABB39680 standard; Peptide; 57 AA.
XX
AC ABB39680;
XX
DT 04-FEB-2002 (first entry)
XX
DE Peptide #7186 encoded by human foetal liver single exon probe.
XX
KW Human; foetal liver, gene expression, single exon nucleic acid probe.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00669.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY 2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03 AUG-2000; 2000US-0632366.
PR 21-SEP 2000; 2000US-0234687.
PR 27-SEP 2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human fetal liver -
XX
PS Claim 27; SEQ ID NO 32315; 639pp + sequence listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for
CC measuring human gene expression in a sample derived from human foetal
CC liver. The single exon nucleic acid probes may be used for predicting,
CC measuring and displaying gene expression in samples derived from human
CC fetal liver. The present sequence is a peptide encoded by a single exon
CC nucleic acid probe of the invention.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 57 AA;

Query Match 65.0%; Score 39; DB 22; Length 57;
Best Local Similarity 72.7%; Pred. No. 27;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 ELMLRLQDYEE 12
||:||||:| |
Db 18 ELILRLQEYFE 28

RESULT 13
AAM60396
ID AAM60396 standard; Protein; 57 AA.
XX
AC AAM60396;
XX
DT 05-NOV-2001 (first entry)

XX
DE Human brain expressed single exon probe encoded protein SEQ ID NO: 32501.
XX
KW Human; brain expressed exon; gene expression analysis; probe;
KW microarray, Alzheimer's disease, multiple sclerosis, schizophrenia,
KW epilepsy; cancer
XX
OS Homo sapiens.
XX
PN WO200157275-A2.
XX
PD 09-AUG-2001
XX
PF 30-JAN-2001; 2001WO-US00667
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483446/52.
XX
PT Single exon nucleic acid probes for analysing gene expression in human
PT brains -
XX
PS Example 4; SEQ ID NO: 32501, 650pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is a protein encoded by one of
CC the probes of the invention.
XX
SQ Sequence 57 AA;

Query Match 65.0%; Score 39; DB 22; Length 57;
Best Local Similarity 72.7%; Pred. No. 27;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 ELMLRLQDYEE 12
||:||||:| |
Db 18 ELILRLQEYFE 28

RESULT 14
AAM73032
ID AAM73032 standard; Protein; 57 AA.
XX
AC AAM73032;
XX
DI 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 33338.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray, cancer, leukaemia, lymphoma, myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00668
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome derived single exon nucleic acid probes useful for
PT analysing gene expression in human bone marrow -
XX
PS Example 4; SEQ ID NO 33338; 658pp + Sequence Listing; English.
XX
CC The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC bone marrow. They can be used to measure gene expression in bone marrow
CC samples, which may enable the improved diagnosis and treatment of cancers
CC such as lymphoma, leukaemia and myeloma. The present sequence is a
CC protein encoded by one of the probes of the invention.
XX
SQ Sequence 57 AA;

Query Match 65.0%; Score 39; DB 22; Length 57;
Best Local Similarity 72.7%; Pred. No. 27;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 2 ELMLRLQDYEE 12
||:||||:| |
Db 18 ELILRLQEYFE 28

RESULT 15
AAM33256
ID AAM33256 standard; Protein; 57 AA.
XX
AC AAM33256;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #7253 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human, placenta, antenatal diagnosis;
KW genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00663.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX

PT Human genome-derived single exon nucleic acid probes useful for
PT analyzing gene expression in human placenta -
XX
PS Claim 27; SEQ ID No 33525; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31415-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders.
XX
SQ Sequence 57 AA;

Query Match 65.0%; Score 39; DB 22; Length 57;
Best Local Similarity 72.7%; Pred. No. 27;
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```
Qy       2 ELMLRLQDYEE 12
           ||:|||||:| |
Db      18 ELILRLQEYFE 28
```

Search completed: January 16, 2003, 16:49:15
Job time : 58.0857 secs